Antiviral and Antivirulence Drugs

Work in the Empting lab focuses on tackling innovative and difficult-to-address anti-infective targets such as bacterial virulence regulatory systems as well as un(der)explored anti-herpesviral persitance mediators. By this, we aspire to circumvent common resistance mechanisms and to refill the dried out development pipeline. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Leader

Dr Martin Empting

"As academic drug discovery scientists we have a clear mandate to drive innovation in anti-infective research. We achieve this is by unlocking and exploiting new modes of action for the treatment of viral and bacterial infections through medicinal chemistry methods."

Dr Martin Empting

Dr. Martin Empting studied chemistry at the Technical University Darmstadt. After receiving his Diploma, which was awarded with the Prize of the “Dr. Anton-Keller-Stiftung”, he performed his PhD studies under supervision of Prof. Dr. Harald Kolmar. In 2013, he graduated with summa cum laude and his doctoral thesis focusing on peptidic drug candidates and biomimetic concepts was awarded with the Prize of the "Familie Bottling-Stiftung". After a PostDoc with Prof. Dr. Rolf W. Hartmann at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) where he focused on the design and optimization of novel anti-infective agents against Gram-negative bacteria, he now conducts his own independent research. His central aim is to devise novel synthetic drug molecules for the development of urgently needed antiinfective therapies.

Further Information

A current overview of the team and further information about the research group can be found on the HIPS page.

PrintSend per emailShare